Lido Advisors LLC Lowers Stock Holdings in Stryker Corporation $SYK

Lido Advisors LLC reduced its stake in Stryker Corporation (NYSE:SYK) by 10.6% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 46,877 shares of the medical technology company’s stock after selling 5,549 shares during the period. Lido Advisors LLC’s holdings in Stryker were worth $15,439,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of SYK. Sankala Group LLC bought a new position in Stryker in the fourth quarter worth approximately $26,000. Godfrey Financial Associates Inc. purchased a new position in Stryker during the 4th quarter worth $26,000. United Financial Planning Group LLC bought a new stake in Stryker during the 3rd quarter valued at $27,000. Atlas Capital Advisors Inc. bought a new stake in Stryker during the 4th quarter valued at $27,000. Finally, DJE Kapital AG purchased a new stake in shares of Stryker in the 4th quarter worth $28,000. 77.09% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on SYK. Robert W. Baird set a $385.00 price target on Stryker in a research report on Friday, May 1st. Argus set a $370.00 price objective on Stryker in a report on Thursday, July 9th. Wall Street Zen lowered shares of Stryker from a “buy” rating to a “hold” rating in a research note on Saturday, May 16th. Citigroup dropped their target price on shares of Stryker from $420.00 to $385.00 and set a “buy” rating on the stock in a report on Tuesday, April 7th. Finally, Wells Fargo & Company cut their target price on shares of Stryker from $456.00 to $418.00 and set an “overweight” rating on the stock in a research report on Friday, May 1st. One analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $392.52.

Stryker Price Performance

Shares of NYSE SYK opened at $319.15 on Friday. Stryker Corporation has a fifty-two week low of $281.00 and a fifty-two week high of $404.14. The company has a market cap of $122.35 billion, a PE ratio of 36.94, a P/E/G ratio of 1.98 and a beta of 0.77. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.25 and a current ratio of 2.11. The business has a 50-day simple moving average of $314.21 and a two-hundred day simple moving average of $335.70.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Thursday, April 30th. The medical technology company reported $2.60 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.98 by ($0.38). The company had revenue of $6.02 billion for the quarter, compared to analyst estimates of $6.34 billion. Stryker had a net margin of 13.20% and a return on equity of 23.42%. The business’s revenue was up 2.6% compared to the same quarter last year. During the same quarter last year, the company earned $2.84 EPS. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. As a group, equities analysts expect that Stryker Corporation will post 14.99 EPS for the current fiscal year.

Stryker Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Tuesday, June 30th will be given a dividend of $0.88 per share. The ex-dividend date of this dividend is Tuesday, June 30th. This represents a $3.52 dividend on an annualized basis and a yield of 1.1%. Stryker’s payout ratio is currently 40.74%.

Insiders Place Their Bets

In related news, VP Robert S. Fletcher sold 4,544 shares of Stryker stock in a transaction dated Thursday, May 28th. The stock was sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the completion of the sale, the vice president owned 10,582 shares of the company’s stock, valued at $3,247,298.34. The trade was a 30.04% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP M Kathryn Fink sold 3,500 shares of the company’s stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $283.45, for a total value of $992,075.00. Following the completion of the sale, the vice president owned 177 shares in the company, valued at approximately $50,170.65. This represents a 95.19% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 323,264 shares of company stock valued at $100,659,489. 4.60% of the stock is owned by company insiders.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.